par Chierchia, Gian-Battista;Di Giovanni, Giacomo;Ciconte, Giuseppe;de Asmundis, Carlo;Conte, Giulio;Sieira Rodriguez-Moret, Juan Antonio ;Rodriguez-Mañero, Moises;Casado Arroyo, Ruben ;Baltogiannis, Giannis;Namdar, Mehdi;Saitoh, Yukio;Paparella, Gaetano;Mugnai, Giacomo;Brugada, Pedro
Référence Europace
Publication Publié, 2014-01
Référence Europace
Publication Publié, 2014-01
Article révisé par les pairs
Résumé : | The novel cryoballoon Advance (CB-A) has proven to achieve significantly lower temperatures and faster pulmonary vein isolation (PVI) times in comparison with the first-generation device. Although acutely very effective, to the best of our knowledge, data on mid-term clinical follow-up is lacking.AIMS: The aim of the study was to analyse the freedom from recurrence of atrial fibrillation (AF) on a 1-year follow-up period, in a series of consecutive patients having undergone PVI with the CB-A for paroxysmal AF (PAF).METHODS AND RESULTS: Forty-two patients [30 male (71%); mean age: 57.9 ± 21.1 years] were included. All patients underwent a procedure with the large 28 mm CB-A. A total 168 PVs were depicted on the pre-procedural computed tomography scan. All PVs (100%) could be isolated with the CB only. The freedom from AF off-antiarrhythmic drug treatment after a single procedure was 78% of patients at a mean 11.6 ± 2.0 months follow-up. If considering a blanking period (BP) of 3 months, success rate was 83%. Phrenic nerve palsy (PNP) was the most frequent complication occurring in 19% of individuals.CONCLUSION: The CB-A is very effective in producing PVI and affords freedom from AF at 12 months follow-up in 83% of patients affected by drug-resistant PAF following a 3-month BP. The most frequent complication observed was PNP which occurred in 19% of patients. All PNP reverted during follow-up. |